Name: Latest research reports of Alivus Life Sciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer

910.9000 -3.45 (-0.38%)

NSE Mar 04, 2026 15:49 PM

25.65% Fall from 52W High

Volume: 68,347

Alivus Life Sciences Ltd.

29 Apr 2023

910.90

-0.38%

Glenmark Life Sciences (BUY): All-round beat

Buy: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API

Alivus Life Sciences Ltd.'s price crossed below 100Day SMA today